pre-IPO PHARMA

COMPANY OVERVIEW

Forendo Pharma is a drug development company, with core competence in tissue specific hormone mechanisms. They are world leading innovators in the endometriosis field, with two active programs. Fispemifene is their men’s health program, for the treatment of male urological conditions.


LOCATION

  • Turku, , Finland
  • Oulu, , Finland

  • THERAPEUTIC AREAS

  • Oncology
  • Urology
  • Women's Health

  • WEBSITE

    https://forendo.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    innovestor karolinska-development-ab m-ventures novartis-venture-fund novo-holdings sunstone-lifescience-ventures vesalius-biocapital


    PRESS RELEASES


    Dec 13, 2021

    Organon Completes Acquisition of Forendo Pharma


    Nov 11, 2021

    Organon to Acquire Forendo Pharma


    Nov 11, 2021

    Organon acquires Karolinska Development’s portfolio company Forendo Pharma at a total purchase price of USD 945 million provided fulfilment of all milestones


    Mar 3, 2021

    Forendo Pharma Successfully Completes Phase 1 Studies of FOR-6219 in Endometriosis, Aiming to Advance Program into Phase 2 Clinical Studies


    Mar 3, 2021

    Karolinska Development’s portfolio company Forendo Pharma advances FOR-6219 to Phase 2 based on positive Phase 1 data


    For More Press Releases


    Google Analytics Alternative